Market closedNon-fractional
Biomea Fusion/BMEA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Biomea Fusion
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
Ticker
BMEA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Redwood City, United States
Employees
110
Website
biomeafusion.com
Biomea Fusion Metrics
BasicAdvanced
$196M
Market cap
-
P/E ratio
-$3.57
EPS
-0.54
Beta
-
Dividend rate
Price and volume
Market cap
$196M
Beta
-0.54
Financial strength
Current ratio
5.843
Quick ratio
5.738
Long term debt to equity
5.857
Total debt to equity
8.197
Management effectiveness
Return on assets (TTM)
-60.99%
Return on equity (TTM)
-116.52%
Valuation
Price to book
1.45
Price to tangible book (TTM)
1.45
Price to free cash flow (TTM)
-1.854
Growth
Earnings per share change (TTM)
10.89%
3-year earnings per share growth (CAGR)
55.37%
What the Analysts think about Biomea Fusion
Analyst Ratings
Majority rating from 8 analysts.
Biomea Fusion Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$39M
12.07%
Profit margin
0.00%
NaN%
Biomea Fusion Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.70
-$0.80
-$0.98
-$1.09
-
Expected
-$0.88
-$0.82
-$0.85
-$0.99
-$1.07
Surprise
-20.01%
-2.81%
15.09%
9.64%
-
Biomea Fusion News
AllArticlesVideos
Biomea Fusion Incorporated Shareholders With Losses Are Encouraged By The Schall Law Firm To Reach Out As It Initiates An Investigation Into Allegations
Accesswire·3 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEA
GlobeNewsWire·8 hours ago
Biomea Fusion Incorporated Shareholders With Losses Are Encouraged By The Schall Law Firm To Reach Out As It Initiates An Investigation Into Allegations
Accesswire·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Biomea Fusion stock?
Biomea Fusion (BMEA) has a market cap of $196M as of July 27, 2024.
What is the P/E ratio for Biomea Fusion stock?
The price to earnings (P/E) ratio for Biomea Fusion (BMEA) stock is 0 as of July 27, 2024.
Does Biomea Fusion stock pay dividends?
No, Biomea Fusion (BMEA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Biomea Fusion dividend payment date?
Biomea Fusion (BMEA) stock does not pay dividends to its shareholders.
What is the beta indicator for Biomea Fusion?
Biomea Fusion (BMEA) has a beta rating of -0.54. This means that it has an inverse relation to market volatility.
Buy or sell Biomea Fusion stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.